News

The randomized, parallel-group, double-blind, placebo-controlled Kinect 3 trial includes around 240 subjects with moderate to severe tardive dyskinesia and an underlying diagnosis of mood disorder, schizophrenia or schizoaffective

As part of the deal, Janssen will secure rights to develop and commercialize ADC-1013, an agonistic fully human monoclonal antibody, that targets CD40, an immuno-stimulatory receptor found on

As part of the three-year deal, several collaborative studies will be conducted in tumor types such as gastroesophageal adenocarcinoma, pancreatic adenocarcinoma and hepatocellular carcinoma. Under the deal, the

This study evaluated the safety and technical feasibility of a single treatment of vonapanitase via a drug-delivery catheter on atherosclerotic human arteries. The data indicate that catheter-based treatment

The phase 3 trial is designed as a randomized, double-blind, placebo-controlled study of about 400 HLA-A2 positive subjects, which will be conducted at about 120 sites in the

In addition to the high efficacy, the results showed an excellent tolerability and safety profile with low risk of hypoglycemia or other side effects (such as gastrointestinal discomfort)

The availability of Karbinal ER provides physicians with a new, effective and easy to use treatment option for children with seasonal and perennial allergic rhinitis that need symptomatic

As part of the deal, CMC will develop a CHEF1 production cell line and process for manufacture of MVI’s monoclonal antibody, targeting circumsporozoite protein (CSP), for use by

SinoVeda Canada has signed an exclusive license agreement with Exzell Pharma to commercialize Effecti-Cal in Canada, the US, Australia and New Zealand. The agreement includes upfront and milestone